Recurrent Melanoma Completed Phase 1 / 2 Trials for DB00570 (Vinblastine)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01196416Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaTreatment